ADMA250117C11000
- 7.10
- 0.000.00%
ADMA Biologics Newsroom
ADMA Biologics Inc. (ADMA): Why Should You Buy This Growth Stock For The Next 5 Years?
Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating
ADMA Reports 2024 Preliminary Revenue Of $ $417M-425M ($422.39M Est.) With With Over $100M Cash, Projects FY 2025 Revenue Over $485M And FY 2026 Above $600M
Express News | ADMA Biologics Inc FY2025 Rev View $484.5 Mln -- LSEG IBES Data
Press Release: ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update
ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update
ADMA Stock Catapults 275.7% in a Year: How Should You Play the Stock?
Adma Biologics (ADMA) Surpasses Market Returns: Some Facts Worth Knowing
ADMA Biologics to Participate in the J.P. Morgan Healthcare Conference on January 13, 2025
Will Weakness in ADMA Biologics, Inc.'s (NASDAQ:ADMA) Stock Prove Temporary Given Strong Fundamentals?
Why Is ADMA Biologics, Inc. (ADMA) Among the Best Multibagger Stocks to Buy Right Now?
The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow
ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility
4 Biotech Stocks Most Wall Street Analysts Are Bullish About
Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Announces Target Price $28
Express News | ADMA Biologics Inc : Mizuho Raises Target Price to $28 From $24
ADMA Stock Falls 19% From Its 52-Week High: Should You Buy the Dip?
Looking Into ADMA Biologics's Recent Short Interest
Can Adma Biologics (ADMA) Climb 25.5% to Reach the Level Wall Street Analysts Expect?